Matinas BioPharma Holdings (MTNB) Equity Average (2014 - 2026)

Matinas BioPharma Holdings (MTNB) has 13 years of Equity Average data on file, last reported at $3.9 million in Q1 2026.

• Equity Average for Q1 2026 came in at $3.9 million, down 43.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.9 million (down 43.35% YoY), and the FY2025 annual result was $6.2 million, down 53.72% from the prior year.
• Equity Average eased to $3.9 million in Q1 2026 per MTNB's latest filing, from $5.6 million in the prior quarter.
• Over five years, Equity Average peaked at $50.1 million in Q1 2022 and troughed at $3.9 million in Q1 2026.
• A 5-year average of $22.3 million and a median of $17.4 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2025: Equity Average declined 23.11% in 2022, then tumbled 59.48% in 2025.
• A 5-year view of Equity Average shows it stood at $37.6 million in 2022, then sank by 43.66% to $21.2 million in 2023, then slumped by 44.88% to $11.7 million in 2024, then tumbled by 51.69% to $5.6 million in 2025, then tumbled by 30.45% to $3.9 million in 2026.
• Business Quant data shows MTNB's Equity Average at $3.9 million in Q1 2026, $5.6 million in Q4 2025, and $7.1 million in Q3 2025.